This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Limburg, P. J. Articles by Albanes, D. Search for Related Content PubMed PubMed Citation Articles by Limburg, P. J. Articles by Albanes, D.

Helicobacter Pylori Seropositivity and Colorectal Cancer Risk

A Prospective Study of Male Smokers¹

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905 [P. J. L.]; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892 [R. Z. S-S., D. A.]; Division of Clinical Sciences, National Cancer Institute 20892 [L. H. C., P. R. T.]; Department of Medicine, New York University School of Medicine and Veterans Affairs Medical Center, New York, New York 10016 [G. I. P-P., M. J. B.]; and the National Public Health Institute, 00300 Helsinki, Finland [J. V.]

Because Helicobacter pylori colonization can produce systemic as well as local effects, it may be associated with carcinogenesis in extra gastric target organs. The currently available data regarding a possible link between H. pylori seropositivity and colorectal cancer risk are limited and inconclusive. In this prospective case-control study nested within the Alpha-Tocopherol, Beta-Carotene Study cohort of Finnish male smokers aged 50–69 years, we examined the association between H. pylori seropositivity and incident colorectal adenocarcinoma. Separate risk estimates were derived by colorectal cancer anatomical subsite and by H. pylori CagA seropositivity status. Demographic, dietary, and lifestyle variables were accounted for in the data analyses using information obtained from a prerandomization questionnaire and physical examination. Baseline serum samples from 118 cases and 236 matched controls were assayed for both H. pylori whole cell and H. pylori CagA antibodies. In total, 258 (73%) and 212 (60%) subjects expressed whole cell and CagA antibodies, respectively. H. pylori seropositivity, defined as one or both antibody assays positive, was present in 273 (77%) subjects. None of the seropositivity results were statistically different between cases and controls. Multivariate odds ratio (95% confidence interval) estimates for whole cell, cagA, and H. pylori seropositivity were 1.05 (0.63–1.74), 1.17 (0.74–1.84), and 0.91 (0.53–1.55), respectively. Stratification by colorectal cancer subsite yielded similarly unremarkable results. On the basis of these data, H. pylori carriage does not appear to be an important risk factor for colorectal adenocarcinoma.

This article has been cited by other articles:

				H. Brenner, V. Arndt, C. Stegmaier, H. Ziegler, and D. Rothenbacher Is Helicobacter pylori Infection a Necessary Condition for Noncardia Gastric Cancer? Am. J. Epidemiol., February 1, 2004; 159(3): 252 - 258. [Abstract] [Full Text] [PDF]

				R. Z Stolzenberg-Solomon, K. W Dodd, M. J Blaser, J. Virtamo, P. R Taylor, and D. Albanes Tooth loss, pancreatic cancer, and Helicobacter pylori Am. J. Clinical Nutrition, July 1, 2003; 78(1): 176 - 181. [Abstract] [Full Text] [PDF]